Mineralys Therapeutics Inc
MLYS13.620USD
-0.045-0.33%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
883.61MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Mineralys Therapeutics Inc Unternehmen
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Unternehmensinformationen
BörsenkürzelMLYS
Name des UnternehmensMineralys Therapeutics Inc
IPO-datumFeb 10, 2023
CEOMr. Jon Congleton
Anzahl der mitarbeiter51
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 10
Addresse150 N. Radnor Chester Road
StadtRADNOR
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl19087
Telefon18883786240
Websitehttps://mineralystx.com/
BörsenkürzelMLYS
IPO-datumFeb 10, 2023
CEOMr. Jon Congleton
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 19
Aktualisiert: Sat, Jul 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
Aktionäre
Aktionäre
Anteil
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
38.81%
Hedge Fund
23.09%
Venture Capital
22.96%
Investment Advisor/Hedge Fund
16.44%
Individual Investor
1.40%
Research Firm
1.10%
Pension Fund
0.67%
Private Equity
0.61%
Bank and Trust
0.09%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
285
69.20M
106.19%
+10.20M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
2023Q1
99
41.30M
101.10%
+30.53M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Catalys Pacific, LLC
8.64M
13.26%
--
--
Mar 31, 2025
RA Capital Management, LP
6.15M
9.43%
+1.30M
+26.72%
Mar 31, 2025
Samsara BioCapital, LLC
5.67M
8.71%
+600.00K
+11.82%
Mar 31, 2025
SR One Capital Management, LP
3.13M
4.8%
+1.11M
+55.09%
Mar 31, 2025
TCG Crossover Management, LLC
2.47M
3.79%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
2.30M
3.53%
+1.43M
+162.86%
Mar 31, 2025
HBM Partners AG
2.25M
3.45%
--
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.20M
3.38%
+266.41K
+13.75%
Mar 31, 2025
Caligan Partners, LP
2.15M
3.3%
+1.14M
+112.60%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.82%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.12%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.06%
iShares Russell 2000 Growth ETF
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.82%
SPDR S&P Biotech ETF
Anteil0.2%
iShares Micro-Cap ETF
Anteil0.12%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.11%
ProShares Ultra Nasdaq Biotechnology
Anteil0.1%
Invesco Nasdaq Biotechnology ETF
Anteil0.1%
iShares Biotechnology ETF
Anteil0.06%
iShares Russell 2000 Growth ETF
Anteil0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0.03%
ProShares UltraPro Russell2000
Anteil0.02%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
